Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$34.05 – $37.43
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $167.48B | $168.05B | $150.51B | $155.25B | $166.26B | $173.46B | $165.60B | $165.89B |
| Cost of revenue | $64.36B | $64.70B | $65.25B | $66.48B | $73.93B | $77.08B | $78.00B | $86.38B |
| Gross profit | $103.12B | $103.35B | $85.27B | $88.77B | $92.33B | $96.38B | $87.60B | $79.51B |
| Gross margin | 61.6% | 61.5% | 56.6% | 57.2% | 55.5% | 55.6% | 52.9% | 47.9% |
| R&D | $7.03B | $7.11B | $7.34B | $7.52B | $8.33B | $9.00B | $9.11B | $9.13B |
| Operating income | $26.29B | $26.36B | $25.94B | $26.07B | $26.67B | $25.78B | $24.86B | $14.86B |
| EBITDA | $29.59B | $30.95B | $29.91B | $30.79B | $31.86B | $33.65B | $21.96B | $23.61B |
| Net income | $18.02B | $19.14B | $19.20B | $19.71B | $20.02B | $20.34B | $10.07B | $3.66B |
| Net margin | 10.8% | 11.4% | 12.8% | 12.7% | 12.0% | 11.7% | 6.1% | 2.2% |
| EPS (diluted) | 227.95 | 244.08 | 245.71 | 252.36 | 259.59 | 268.16 | 135.42 | 49.19 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $173.1B | $140.93 | $138.16–$142.87 | 1 |
| 2027 | $180.4B | $185.24 | $181.60–$187.78 | 1 |
| 2028 | $187.2B | $226.95 | $222.49–$230.07 | 1 |
| 2029 | $191.8B | $237.04 | $232.38–$240.30 | 1 |
Forward consensus · source: Financial Modeling Prep
KOBAYASHI PHARM CO ORD
No one on the platform currently holds KBYPF.
No tracked institution reports a position in KBYPF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-12-31 | $61.0000 | |
| 2026-06-30 | $45.0000 | |
| 2025-12-31 | $60.0000 | 2026-03-09 |
| 2025-06-30 | $44.0000 | 2025-09-04 |
| 2024-12-31 | $59.0000 | 2025-03-14 |
| 2024-06-28 | $43.0000 | 2024-09-05 |
| 2023-12-29 | $58.0000 | 2024-03-07 |
No one on the platform has traded KBYPF yet.
| +0.00% |
| $1.8B |
| — |
| LIOPFLion Corporation | $11.51 | +0.00% | $3.2B | — |
| MIOFFMilbon Co., Ltd. | $52.60 | +0.00% | $1.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.